Loading...
•
Dec 31, 2020
Amneal Q4 2020 Earnings Report
Amneal's financial performance was reported for Q4 2020, with net revenue increasing and a net loss decreasing compared to the previous year.
Key Takeaways
Amneal Pharmaceuticals reported a 28% increase in net revenue to $510 million for Q4 2020. The company experienced a net loss of $3 million, an improvement from the $32 million loss in the same quarter of the previous year. Adjusted diluted EPS was $0.14, compared to $0.08 in the prior year.
Net revenue increased by 28% to $510 million compared to Q4 2019.
GAAP net loss improved to $3 million from a $32 million loss in the prior year.
Adjusted EBITDA increased by 33% to $107 million.
Adjusted diluted EPS increased to $0.14 from $0.08 in the prior year.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal provided its full year 2021 financial guidance, with net revenue expected to be between $2.1 billion and $2.2 billion and adjusted diluted EPS between $0.70 and $0.85.
Positive Outlook
- Net revenue between $2.1 billion - $2.2 billion
- Adjusted EBITDA between $500 million - $540 million
- Adjusted diluted EPS between $0.70 - $0.85
- Operating cash flow between $220 million - $250 million
- Capital expenditures between $60 million - $70 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income